QUEBEC CITY, QUEBEC--(Marketwire - July 15, 2008) - Medicago Inc. (TSX VENTURE: MDG) today announced that it will conduct a feasibility study in collaboration with Genopole biopark, in Evry, for the establishment of a vaccine production facility in France. Medicago has obtained a grant from the Quebec Ministry of Economic Development, Innovation and Export Trade to finance 40% of the study. The study will be conducted by SNC Lavalin with the assistance of Medicago and the Genopole d’Evry.
